Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity to Lead Akero Clas for Investors Who Suffered Significant Losses



San Diego, April 26, 2024 (GLOBE NEWSWIRE) — Robbins Geller Ruderman & Dodd LLP Announced that a class action lawsuit has been filed seeking to represent persons who purchased Akero Therapeutics, Inc. (NASDAQ: ) common stock between September 13, 2022 and October 9, 2023, inclusive (the Class Period). buyers. The Akero class action lawsuit, titled Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (Calif. NC), alleges that Akero and certain of its senior officers violated the Securities Exchange Act of 1934.

If you have suffered significant losses and wish to serve as lead plaintiff the bus CLASS ACTION, PLEASE PROVIDE YOUR INFORMATION HERE:

https://www.rgrdlaw.com/cases-akero-therapeutics-inc-class-action-lawsuit-akro.html

You can also contact a lawyer J.C. Sanchez or Jennifer N. Carringer To contact Robbins Geller, call 800/449-4900 or email info@rgrdlaw.com.lead plaintiff motion the bus The class action lawsuit must be filed in court by June 25, 2024.

case charges: Akero is a clinical-stage biopharmaceutical company focused on advancing its lead product candidate, efruxifermin (EFX), to provide new treatments for patients with non-alcoholic steatohepatitis (NASH), a serious liver disease. During the Class Period, Akero claimed that it was evaluating EFX in two Phase 2 clinical trials in patients with biopsy-confirmed NASH: (i) Akero's HARMONY trial tested EFX in patients with precirrhotic NASH; (ii) Akero's SYMMETRY trial reportedly tests EFX in patients with NASH-induced cirrhosis.

The Akero class action lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose throughout the Class Period that: (i) approximately 20% of patients enrolled in the SYMMETRY study had cryptogenic cirrhosis and did not Definite NASH at baseline; (ii) Patients with cryptogenic cirrhosis enrolled in the SYMMETRY study did not have biopsy-confirmed compensated cirrhosis due to definite NASH; (iii) Outcomes for patients with cryptogenic cirrhosis will be excluded from the calculation of the secondary endpoint of NASH response; (iv) Akero introduced confounding factors into the design of the SYMMETRY study that had a significant impact on the potential results of the study and increased the risk that the study would not meet its primary endpoint. ; (v) the SYMMETRY study was inconsistent with the U.S. Food and Drug Administration's guidance on testing drugs to treat cirrhosis in NASH because Akero did not rule out potential causes of cirrhosis other than NASH in each patient; (vi) Akero therefore materially misrepresented The nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood of the SYMMETRY trial's success as measured by its primary endpoint, and the likelihood that EFX will be a SYMMETRY trial. of commercial treatment.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

It wasn't until Akero disclosed the 36-week results of the study on October 10, 2023, that the market finally began to understand the truth, with Akero's stock price plummeting nearly 70% In response, according to the Akero class action lawsuit.

The plaintiffs are represented by Robbins Geller, who rich experience Prosecute investor class actions, including those involving financial fraud.You can view a copy of the complaint click here.

lead plaintiff proceeding: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased shares of Akero common stock during the Class Period to seek to be named as lead plaintiff in an Akero class action lawsuit. The lead plaintiff is typically the mover with the greatest financial interest in the relief sought by the putative class and is typical and adequate of the putative class. The lead plaintiff leads the Akero class action on behalf of all other class members. Lead plaintiffs can file the Akero class action lawsuit with the law firm of their choice. An investor's ability to share in any potential future recoveries from the Akero class action lawsuit is not dependent on serving as lead plaintiff.

About Robbins Geller: Robbins Geller is one of the world's leading complex class action firms representing plaintiffs in securities fraud cases. The firm is ranked No. 1 in the ISS Securities Class Action Services Top 50 report, recovering more than $1.75 billion for investors in 2022, ranking Robbins Geller at the top of the list for the third consecutive year. In these three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than twice the amount recovered by other plaintiff firms. With 10 offices and 200 attorneys, Robbins Geller is one of the largest plaintiffs firms in the world, and the firm's attorneys have secured many of the largest securities class action recoveries in history, including the largest ever, The amount is “US$7.2 billion.” litigation. Please visit the following pages for more information:

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Lawyer advertising.
Past results are no guarantee of future results.
Services can be provided by attorneys in any of our offices.

touch:
Robbins Geller Ruderman & Dodd LLP
J.C. Sanchez, Jennifer N. Carringer
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *